GlassScriptPhysician profile
Susan J Cheng
NPI 1427439124
$3,441.75
in general payments reported to CMS, 2019-2025
47 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $451 · 2021: $495 · 2022: $632 · 2023: $470 · 2024: $605 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.95 | 2020-2025 | Ubrelvy, Linzess, Qulipta |
| Amgen INC. | $596.49 | 2019-2025 | Evenity, Prolia |
| Abbott Laboratories | $239.33 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $212.83 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $150.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $133.87 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Glaxosmithkline, LLC. | $116.81 | 2022-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $106.74 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $85.24 | 2019-2021 | |
| Lilly USA, LLC | $75.23 | 2020-2022 | |
| Nevro Corp. | $62.76 | 2022-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.42 | 2019-2025 | Xifaxan |
| Grifols USA, LLC | $56.63 | 2024-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $49.78 | 2021 | |
| Esperion Therapeutics, INC. | $47.72 | 2021-2023 | Nexletol |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.